CompletedNot applicableNCT01817686

Study of Default Options in Advance Directives

Default options represent the events or conditions that are set into place if no alternatives are actively chosen. The setting of default options has well-established effects on a broad range of human decisions, but its influence on patients' preferences for end-of-life care is only beginning to be understood. This is a 3-armed randomized clinical trial in Veterans at high risk for critical illness, assessing the impact of Advance Directive (AD) forms framed with different default options. The central goals are to assess how default options in ADs influence the end-of-life care choices made by patients at risk for critical care, and these patients' hospital and ICU utilization. The investigators hypothesize that setting defaults in real ADs will increase the proportion of Veterans selecting comfort-oriented plans of care, decrease selections of life-extending therapies such as mechanical ventilation and dialysis, and reduce the proportion of time during follow-up that Veterans spend in the hospital and/or ICU, without affecting patient satisfaction with end-of-life care planning.

Checked against the public recordLast updated Jun 30, 2015 · Source: ClinicalTrials.gov

StatusCompleted
PhaseNot applicable
U.S. locations1
SponsorCorporal Michael J. Crescenz VA Medical Center
01
Study overview

What this study is about

Purpose
Health Services Research
Study type
Interventional
Phase
Not applicable
Sponsor
Corporal Michael J. Crescenz VA Medical Center
Interventions being studied
Other: Comfort Default AD forms; Other: Life Extension Default AD forms; Other: Standard Default AD forms
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: * Age \> 18 years * Chronic Obstructive Pulmonary Disease (COPD) with severe or very severe airflow obstruction on pulmonary function testing and or receiving or eligible to receive long-term oxygen therapy AND/OR * Idiopathic Pulmonary Fibrosis (IPF) AND/OR * Other interstitial lung disease without curative therapy AND/OR * Any stage 3B or 4 solid tumor AND/OR * Congestive Heart Failure (CHF) either New York Heart Association NYHA) class IV or NYHA class III plus 1 hospitalization in the past year * No previously signed advance directive in the medical record * Neither listed for nor considering lung or heart transplantation * High anticipated risk for critical illness in the next 2 years based on clinical judgment * Interest in thinking about filling out an Advance Directive Exclusion Criteria: * Diseases for which life-extending medical therapies may be available * Inability to speak and/or read English proficiently * New clinic patients meeting the clinic provider for the first time * Patients being actively evaluated or already listed for transplants * Patients already having an AD * Cognitive impairment necessitating proxy consent

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Philadelphia Veterans Affairs Medical CenterPhiladelphia, Pennsylvania

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 30, 2015. Always confirm current availability with the study team.

View original record ↗